Emcure`s Initiatives in Anemia Management
Download
Report
Transcript Emcure`s Initiatives in Anemia Management
Emcure’s Initiatives in
Anemia Management
Dr. P. Bhandari, M.D.
1
Emcure
Research driven pharmaceutical company
Therapeutic areas
Responsible corporate citizen
Anemia
giving back to society from which it profits
AIDS
Cardiology
Nephrology
Oncology
Gynecology
Diabetes
Neurology
We bring difference in lives
Orthopedics
Gastroenterology
2
Anemia – a global problem
According to a survey conducted by NFHS, the prevalence of anaemia in young girls
aged between 15-24 years is 56% with higher rates in rural than in urban India.
3
Anemia affects all
Mother
Pre-term delivery
Fetal and maternal mortality
Low birth weigh baby
Child
Impaired mental function
Increased infections
Frequent diarrhea
4
Anemia – signs/symptoms
Fatigue (very common)
Weakness (very common)
Dizziness
Shortness of breath
Irritability
Lack of concentration
Pale skin and tongue
Brittle nails
Low hemoglobin
Iron deficiency anaemia with depapillated
tongue, depigmentation of the upper lip
and epithelial erosion of the lower lip
5
Emcure in Anaemia management
Innovative oral iron products:
Ferrous ascorbate tablets, suspension,
etc.
State of the art parenteral iron
products:
Iron sucrose injection
Ferric carboxymaltose injection
Biotechnology products:
Erythropoietin
6
Ferrous Ascorbate
Leaders in the ferrous ascorbate market
Offering own R&D ferrous ascorbate
Granted Indian Patent
The best oral iron so far:
Maximum bioavailability of up to 43%
Excellent tolerability
Prevents inhibitory action of dietary phytates etc
Proven safety and efficacy
Dose: 100 mg elemental iron daily for adults
7
Why Ferrous Ascorbate?
Inhibitors
The absorption of iron from ordinary iron
supplements is approximately 10% or less
This is due to presence of inhibitory ligands
like phytates, tannins, phosphates etc in food
Facilitators
The presence of ascorbate facilitates
absorption by preventing the action of these
inhibitory ligands
This increase absorption of iron from ferrous
ascorbate up to 43%
8
When oral iron may not be sufficient?
In severe anemia that will require very long time to
correct
Very low iron stores that need quick replenishment
In renal failure patients who do not respond to oral
iron
In menorrhagia-associated severe iron-deficiency
anemia
In anemia associated with cancer
Parenteral (IV) iron
9
Iron Sucrose Injection
The dominant IV iron for anaemia
management
Does not have risk of dextran-induced
hypersensitivity
Used by both nephrologists and
obstetricians
Dose: 100 mg by slow IV bolus x max thrice
weekly, or 100-200 mg IV infusion x max
thrice weekly, to replenish cumulative deficit
10
Ferric Carboxymaltose Injection
The latest IV iron
Introduced first in India by Emcure
Offers feasibility of total dose infusion
of 1g in 15 min
No dextran-type hypersensitivity
Safe & effective in different
indications
11
Erythropoietin
Manufactured in Gennova
Biopharmaceuticals facility of Emcure
Matching European Pharmacopoeia
standards
Used by nephrologists in renal anemia
Used by obstetricians in EPO-deficient
IDA in pregnancy
12
FOGSI – Emcure Social Responsibility
13
Emcure’s Corporate Social Responsibility
14
Emcure’s Corporate Social Responsibility
15
Emcure’s Corporate Social Responsibility
16
Emcure’s Corporate Social Responsibility
17
FOGSI-Emcure Publications
http://haemoglobin-anaemia.com/fogsipublication.asp
18
Emcure in Anemia Management
Latest research and development
Quality products
Education, awareness and support
through CSR activities
We bring difference in lives
19
Emcure’s websites
www.emcure.co.in
http://haemoglobin-anaemia.com
20